|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
361,099 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mauro David J |
Chief Medical Officer |
|
2015-07-31 |
4 |
D |
$16.66 |
$417 |
D/D |
(25) |
190,342 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2015-07-31 |
4 |
A |
$16.66 |
$1,949 |
D/D |
117 |
190,367 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-07-31 |
4 |
S |
$15.44 |
$45,440 |
D/D |
(2,943) |
135,587 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-07-31 |
4 |
D |
$16.66 |
$1,299 |
D/D |
(78) |
138,530 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-07-31 |
4 |
A |
$16.66 |
$2,932 |
D/D |
176 |
138,608 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-07-31 |
4 |
D |
$16.66 |
$566 |
D/D |
(34) |
94,181 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-07-31 |
4 |
A |
$16.66 |
$2,466 |
D/D |
148 |
94,215 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-07-31 |
4 |
D |
$16.66 |
$733 |
D/D |
(44) |
138,797 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-07-31 |
4 |
A |
$16.66 |
$2,932 |
D/D |
176 |
138,841 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-06-30 |
4 |
D |
$20.33 |
$407 |
D/D |
(20) |
138,665 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-06-30 |
4 |
A |
$20.33 |
$1,952 |
D/D |
96 |
138,685 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-06-30 |
4 |
D |
$20.33 |
$325 |
D/D |
(16) |
94,067 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-06-30 |
4 |
A |
$20.33 |
$1,647 |
D/D |
81 |
94,083 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-06-30 |
4 |
D |
$20.33 |
$264 |
D/D |
(13) |
138,432 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-06-30 |
4 |
A |
$20.33 |
$1,952 |
D/D |
96 |
138,445 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2015-06-30 |
4 |
D |
$20.33 |
$163 |
D/D |
(8) |
346,990 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2015-06-30 |
4 |
A |
$20.33 |
$7,095 |
D/D |
349 |
346,998 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2015-06-30 |
4 |
D |
$20.33 |
$244 |
D/D |
(12) |
190,250 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2015-06-30 |
4 |
A |
$20.33 |
$1,301 |
D/D |
64 |
190,262 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2015-05-29 |
4 |
D |
$25.16 |
$226 |
D/D |
(9) |
190,198 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2015-05-29 |
4 |
A |
$25.16 |
$1,283 |
D/D |
51 |
190,207 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-05-29 |
4 |
D |
$25.16 |
$327 |
D/D |
(13) |
94,002 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-05-29 |
4 |
A |
$25.16 |
$1,635 |
D/D |
65 |
94,015 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2015-05-29 |
4 |
A |
$25.16 |
$7,095 |
D/D |
282 |
358,048 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-05-29 |
4 |
D |
$25.16 |
$277 |
D/D |
(11) |
138,349 |
|
- |
|
465 Records found
|
|
Page 12 of 19 |
|
|